{
    "Trade/Device Name(s)": [
        "cobas c 513 Analyzer",
        "cobas c 513 Tina-quant HbA1cDx Gen.3 Assay"
    ],
    "Submitter Information": "Roche Diagnostics Operations",
    "510(k) Number": "K160571",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121291"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ",
        "JJE"
    ],
    "Summary Letter Date": "December 08, 2016",
    "Summary Letter Received Date": "December 09, 2016",
    "Submission Date": "January 31, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.1373",
        "21 CFR 862.2160"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c test system",
        "Discrete photometric chemistry analyzer for clinical use"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Total Hemoglobin"
    ],
    "Specimen Type(s)": [
        "Whole blood",
        "Hemolysate"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Li-Heparin tube",
        "EDTA/Fluoride tube",
        "NaF/Potassium oxalate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas c 513 Analyzer",
        "Roche/Hitachi clinical chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Turbidimetric inhibition immunoassay (TINIA)",
        "Photometric analysis"
    ],
    "Methodologies": [
        "Quantitative immunoassay",
        "Discrete photometric chemistry"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Assay",
        "Reagent system"
    ],
    "Document Summary": "FDA 510(k) summary for Roche cobas c 513 Analyzer and Tina-quant HbA1cDx Gen.3 assay for quantitative determination of hemoglobin A1c and total hemoglobin in whole blood and hemolysate",
    "Indications for Use Summary": "The cobas c 513 Analyzer is intended for in-vitro quantitative determination of analytes in body fluids; the Tina-quant Hemoglobin A1cDx Gen.3 assay aids in the diagnosis and identification of patients at risk for diabetes and monitoring long-term blood glucose control.",
    "fda_folder": "Clinical Chemistry"
}